Hosted on MSN11mon
Sequana’s DSR therapy shows promise in heart failure patients
Belgium-based Sequana Medical has released data from the Phase I/II MOJAVE study in the US, which is evaluating its direct sodium removal (DRS) therapy in patients with congestive heart failure.
Yahoo Finance27d
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions
Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the 2024 convertible loan with various shareholders, and EUR 2.68 million under the Kreos 2022 loan into ...